论文部分内容阅读
他汀类药物为临床常用的降脂药物,体外及体内的诸多研究表明,他汀类药物具有免疫调节作用。多发性硬化的实验模型研究中,口服他汀类药物可以通过异戊二烯化ras和rho三磷酸酶刺激T细胞分化,从而阻止炎性反应的复发或者转复肢体的无力。2004年《柳叶刀》杂志Vollmer等学者曾经报道辛伐他汀可以减少多发性硬化患者头MRI的新发T2病灶数量。之后有关多发性硬化的治疗研究,多为他汀类药物结合β-干扰素-1a进行。但是在联合β-干扰素-1a治疗的同时,他汀类药物没有和
Statins are commonly used in clinical lipid-lowering drugs, many studies in vitro and in vivo showed that statins have immunomodulatory effects. In an experimental model of multiple sclerosis, oral statin therapy stimulated T cell differentiation by isoprenylation of ras and rho-triphosphatase to prevent the recurrence of inflammatory reactions or to reverse limb weakness. In 2004, “Lancet” magazine Vollmer et al. Have reported that simvastatin can reduce the number of new T2 lesions in head MRI of patients with multiple sclerosis. Subsequent research on the treatment of multiple sclerosis, mostly for statins in combination with β-interferon-1a. However, there was no statin at the same time as the combination of interferon-alpha-1a